Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1099/jmm.0.001372 http://scihub22266oqcxt.onion/10.1099/jmm.0.001372 34309503!8493423!34309503     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Microbiol 2021 ; 70 (7): ä Nephropedia Template TP {{tp|p=34309503|t=2021. Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19 |pdf=|usr=}}{{34309503}} gab.com Text Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19 JO: J Med Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=34309503 #FOAvip Introduction. The ID NOW is FDA approved for the detection of SARS-CoV-2 in symptomatic individuals within the first 7 days of symptom onset for COVID-19 if tested within 1 h of specimen collection.Gap statement. Clinical data on the performance of the ID NOW are limited, with many studies varying in their study design and/or having small sample size.Aim. In this study we aimed to determine the clinical performance of the ID NOW compared to conventional RT-PCR testing.Methodology. Adults with COVID-19 in the community or hospital were recruited into the study. Paired throat swabs were collected, with one throat swab transported immediately in an empty sterile tube to the laboratory for ID NOW testing, and the other transported in universal transport media and tested by an in-house SARS-CoV-2 RT-PCR assay targeting the E gene.Results. In total, 133 individuals were included in the study; 129 samples were positive on either the ID NOW and/or RT-PCR. Assuming any positive result on either assay represents a true positive, positive per cent agreement (PPA) of the ID NOW compared to RT-PCR with 95 % confidence intervals was 89.1 % (82.0-94.1%) and 91.6 % (85.1-95.9%), respectively. When analysing individuals with symptom duration </=7 days and who had the ID NOW performed within 1 h (n=62), ID NOW PPA increased to 98.2 %.Conclusion. Results from the ID NOW were reliable, especially when adhering to the manufacturer's recommendations for testing. Twit Text FOAVip Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19 ????J Med Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=34309503 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34309503 #FOAvip English Wikipedia <ref>{{Cite pmid|34309503}}</ref> Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19 #MMPMID34309503 Stokes W; Berenger BM; Singh T; Adeghe I; Schneider A; Portnoy D; King T; Scott B; Pabbaraju K; Shokoples S; Wong AA; Gill K; Turnbull L; Hu J; Tipples G J Med Microbiol 2021[Jul]; 70 (7): ä PMID34309503show ga Introduction. The ID NOW is FDA approved for the detection of SARS-CoV-2 in symptomatic individuals within the first 7 days of symptom onset for COVID-19 if tested within 1 h of specimen collection.Gap statement. Clinical data on the performance of the ID NOW are limited, with many studies varying in their study design and/or having small sample size.Aim. In this study we aimed to determine the clinical performance of the ID NOW compared to conventional RT-PCR testing.Methodology. Adults with COVID-19 in the community or hospital were recruited into the study. Paired throat swabs were collected, with one throat swab transported immediately in an empty sterile tube to the laboratory for ID NOW testing, and the other transported in universal transport media and tested by an in-house SARS-CoV-2 RT-PCR assay targeting the E gene.Results. In total, 133 individuals were included in the study; 129 samples were positive on either the ID NOW and/or RT-PCR. Assuming any positive result on either assay represents a true positive, positive per cent agreement (PPA) of the ID NOW compared to RT-PCR with 95 % confidence intervals was 89.1 % (82.0-94.1%) and 91.6 % (85.1-95.9%), respectively. When analysing individuals with symptom duration |*COVID-19 Nucleic Acid Testing[MESH] |Adult[MESH] |COVID-19/*diagnosis[MESH] |False Negative Reactions[MESH] |False Positive Reactions[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Nucleic Acid Amplification Techniques[MESH] |Reproducibility of Results[MESH]Acceptable performance of the Abbott ID NOW among symptomatic individu(epmc).pdf DeepDyve Pubget Overpricing